1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Recalls

Magellan Lead Test Recall Expanded After First Attempted Fix Found Insufficient

 
• By Elizabeth Orr

Several additional batches of Magellan’s LeadCare II tests are being recalled as efforts to address the root cause continue.

Laboratory assistant putting test tubes into the holder, Close-up view focused on the tubes
• Source: Shutterstock

Magellan Diagnostics has expanded a recall of its blood tests for lead after learning an initial fix hadn’t resolved the issue, the company announced on 1 September.

The company first recalled its LeadCare II, LeadCare Plus and LeadCare Ultra Blood Lead Tests in May because the tests...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Recalls

FDA Warning Letter To Philips Targets Three Facilities For Quality Control Failures

 
• By Brian Bossetta

US FDA inspections of three Philips manufacturing sites earlier this year resulted in a September warning letter that claimed the company was not in conformity with current good manufacturing practices. Philips says it is addressing the agency’s concerns and working to enhance its quality systems.

US FDA Plans Move Inspectorate Back To More Generalist Organization

 
• By Sarah Karlin-Smith and Derrick Gingery

The “Simple Reform” initiative would reverse a 2017 move to ensure FDA investigators were experts in the commodity they inspected or in clinical research regulations.

Philips S&RC CEO Leonard Talks Respironics Recall Lessons

 
• By Ashley Yeo

The recall of various Respironics sleep and respiratory care devices in 2021 plunged Philips into static growth and market share loss. Careful remediation is the group’s top priority, but S&RC head Dan Leonard is determined that the manner of its achievement will be the envy of the industry.

After Success Of Early Alert Pilot, FDA Builds Out Program To Include All Devices

 
• By Brian Bossetta

The US FDA’s device center says the pilot program launched last year to streamline its recall process has been a success. It’s now starting to build off the program’s achievements, which means patients could be aware of potential safety issues from more types of devices.

More from Policy & Regulation

Smaller Companies Next Frontier for FDA’s Voluntary Improvement Program

 
• By Elizabeth Orr

At the Medical Device Innovation Consortium summit, Cogmedix's Scott Cook discussed the challenges and benefits of transitioning to the FDA's Voluntary Improvement Program, which promotes honesty and opportunities for improvement, leading to faster market access and cost savings.

Italy’s Responsible Person Sanctions Approach Raises Eyebrows

 
• By Amanda Maxwell

Fines are a fact of life when it comes to manufacturers’ compliance with EU rules on persons responsible for regulatory compliance. But Italy’s stance adds pressure on individuals appointed to the role.

A Trillion On The Table. Addressing Disparities In Women’s Health Isn’t Just Right. It’s Smart.

 
• By Brian Bossetta

Advocates spanning the spectrum of women’s health met in Manhattan to discuss the gender disparities that remain in healthcare and how public policy can correct them and the enormous ROI investors in women’s health can potentially reap.